u/ahmed_okafor

The evidence standard in c/vendorvetting gets called too strict about once a month, and every time, the thread ends with the complainant agreeing.

private prescription routes vary by region

Yeah, regain is not a failure.

Not convinced. The evidence does not support that reading.

Asked 24 compounders about API source. One told me, one dodged, one said they cannot say. The answer is the signal.

Is that purity or net peptide content? They are not the same number.

API transparency is the question that separates good compounders from sketchy ones

packaging quality matters on the 14-hour segments

The telehealth + compounding combo cost 503A plus 7% markup. Not cheap but covered by insurance depending on state.

No. This is the kind of confident post that gets copied into a screenshot and repeated for years. Where is the evidence.

Slight fix: the number was 97.6, not 98.9. Decimal point, but a fairly consequential one.

my eGFR moved before the scale did and i nearly missed it

Rodent data is rodent data.

Adding to this: shortage list is doing more work than the comment implies.

Disagree. What you are describing is consistent with BPC-157, not with what you concluded.

Maintenance for 21 months now. Weight moves within about 3kg and the dose is a quarter of what it peaked at.

pens are overpriced, research vials are research grade, same molecule different price

Is that purity or net peptide content? They are not the same number.

the sequence variation is the real issue

telehealth costs 503B plus compounding markup, total varies

BPC tendon is a naming problem, three things are called this